Progressive coronary calcification despite intensive lipid-lowering treatment: A randomised controlled trial

Heart

Volumn 92, Issue 9, 2006, Pages 1207-1212

  Houslay, E S ^b   Cowell, S J ^b   Prescott, R J ^c   Reid, J ^d   Burton, J ^d   Northridge, D B ^e   Boon, N A ^b   Newby, David E ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d BORDERS GENERAL HOSPITAL   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ANAMNESIS; AORTA STENOSIS; ARTERY CALCIFICATION; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCORING SYSTEM;

ADULT; AGED; AORTIC VALVE STENOSIS; CALCINOSIS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; TOMOGRAPHY, SPIRAL COMPUTED; TREATMENT FAILURE;

EID: 33748035081     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.080929     Document Type: Article

References (32)

1. Pletcher MJ, Tice JA, Pignone M, et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and metaanalysis. Arch Intern Med 2004;164:1285-92.
2. Raggi P, Cooil B, Shaw LJ, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003;92:827-9.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholeslerolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
5. Scandinavian Simvastatin Survival Study Investigators, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
6. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
7. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
8. Medical Research Council, British Heart Foundation. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
9. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998;339:1972-8.
10. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002;106:1077-82.
11. Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cordiol 2005;46:166-72.
12. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholeslerolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 2005;112:563-71.
13. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering lherapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
14. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-7.
15. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiograpny. J Am Soc Echocardiogr 2003;16:777-802.
16. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ 1998;317:362-3.
17. Carr JJ, Crouse JR 3rd, Goff DC Jr, et al. Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol 2000;174:915-21.
18. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
19. Shemesh J, Apter S, Rozenman J, et al. Calcification of coronary arteries: detection and quantification with double-helix CT. Radiology 1995;197:779-83.
20. Goldin JG, Yoon HC, Greaser LE 3rd, et al. piral versus electron-beam CT for coronary artery calcium scoring. Radiology 2001;221:213-21.
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
22. Brown H, Prescott R. Applied mixed models in medicine. Chichester: John Wiley and Sons, 1999.
23. Hecht HS, Harman SM. Relation of aggressiveness of lipid-lowering treatment to changes in calcified plaque burden by electron beam tomography. Am J Cardiol 2003;92:334-6.
24. Davies MJ. The composition of coronary-artery plaques. N Engl J Med 1997;336:1312-4.
25. Mintz GS, Popma JJ, Pichard AD, et al. Patterns of calcification in coronary artery disease: a statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation 1995;91:1959-65.
26. Stary HC. The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. Am J Cardiol 2001;88(2A):16E-9E.
27. Daoud AS, Jarmolych J, Augustyn JM, et al. Sequential morphologic studies of regression of advanced atherosclerosis. Arch Pathol Lab Med 1981;105:233-9.
28. Schwartz GG, Oliver MF, Ezekowitz MD, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578-81.
29. Qanadli SD, Mesurolle B, Aegerter P, et al. Volumetric quantification of coronary artery calcifications using dual-slice spiral CT scanner: improved reproducibility of measurements with 180 degrees linear interpolation algorithm. J Comput Assist Tomogr 2001;25:278-86.
30. Collister TQ, Cooil B, Raya SP, et al. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology 1998;208:807-14.
31. Hong C, Becker CR, Schoepf UJ, et al. Coronary artery calcium: absolute quantification in nonenhanced and contrast-enhanced multi-detector row CT studies. Radiology 2002;223:474-80.
32. Rumberger JA, Kaufman L. A Rosetta stone for coronary calcium risk stratification: Agatston, volume, and mass scores in 11,490 individuals. AJR Am J Roentgenol 2003;181:743-8.